DOTA-XYIMSR-01

DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy[1].

Product Specifications

CAS Number

[2051527-54-7]

UNSPSC

12352005

Target

Carbonic Anhydrase

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(NCCOCCOCCNC([C@@H](NC(C[C@@H](C(O)=O)NC(C[C@@H](C(O)=O)NC(CCC(C)(C2=CC=C(O)C=C2)C3=CC=C(O)C=C3)=O)=O)=O)CCCCN4C=C(CCCC(NC5=NN=C(S(=O)(N)=O)S5)=O)N=N4)=O)=O)CC1

Molecular Formula

C61H88N16O22S2

Molecular Weight

1461.58

References & Citations

[1]Wang J, et al. [177Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma. Bioconjug Chem. 2025 Mar 19;36 (3) :588-596.